Turnkey, investment-ready medical cannabis cultivation facility with full SAPHRA cGMP compliance, positioning it at the premium end of both local and international pharmaceutical markets. Established in 2024, the business operates a fully controlled indoor grow environment, ensuring consistent, year-round production with no seasonal risk.
The facility includes modern infrastructure and equipment valued at ±R4.5 million and is supported by documented SOPs, strict quality controls, and batch traceability systems. It is already aligned with export standards and has established offtake relationships in the UK, Germany, and Australia, providing predictable demand and reduced commercial risk.
With a selling price of R8.9 million and a net profit of approximately R3.86 million (ROI ~43%), the business offers immediate income and strong scalability. Growth opportunities include small-batch processing, third-party processing, and expanding export volumes.
This is a rare opportunity to acquire a fully licensed, compliant, and operational facility without the 18–25 month regulatory lead time and ±R4 million setup cost typically required to enter the market.
